Exciting Presentations by Aprea Therapeutics
In an exciting development, Aprea Therapeutics, Inc. (NASDAQ: APRE), a pioneering clinical-stage biopharmaceutical company, is gearing up for the Maxim Healthcare Virtual Summit. The event is set to run from October 15 to 17, 2024, and promises to deliver critical insights into the field of precision oncology.
Leadership Participation
Dr. Oren Gilad, the esteemed President and CEO of Aprea, will be taking center stage during the summit. He will be delivering two key presentations that highlight the latest advancements in the company’s oncology pipeline and innovations in synthetic lethality.
Presentation Details
Aprea’s first session is slated for October 16 and will focus on the Precision and Immune Oncology Panel. This session will take place from 2:00 to 3:00 PM ET and is set to attract attention from various stakeholders interested in cutting-edge oncological therapies.
The second presentation, termed a Fireside Chat, will occur on October 17 from 3:30 to 4:00 PM ET. These discussions will delve into the innovative strategies that Aprea is implementing and its dedication to enhancing patient outcomes through targeted therapies.
Accessing the Summit
The conference will be broadcast live on M-Vest, allowing industry professionals and the public to tune in. Interested individuals must sign up to become M-Vest members to access these valuable presentations.
About Aprea Therapeutics
Aprea Therapeutics is steadfast in its mission to transform cancer treatment through precision oncology. The company is based in Doylestown, Pennsylvania, and its primary focus lies in the development of therapies that utilize synthetic lethality to fight cancer. Their lead product candidate, ATRN-119, is currently in clinical development as a small molecule ATR inhibitor targeted at solid tumors.
In addition to ATRN-119, Aprea has recently introduced an oral small-molecule WEE1 inhibitor, APR-1051, which has also commenced clinical trials. The advancements in their treatment strategies demonstrate Aprea’s commitment to addressing unfulfilled medical needs in oncology.
Investor Relations and Contacts
Aprea is keen on maintaining transparency with its stakeholders and regularly updates its investors through their investor relations website. For those interested in financial and corporate developments, Aprea encourages visits to their official site for the latest updates.
For further inquiries, investors can reach out to Mike Moyer from LifeSci Advisors at mmoyer@lifesciadvisors.com.
Media inquiries can be directed to either Ignacio Guerrero-Ros, Ph.D., or David Schull at Russo Partners, LLC, through their respective emails.
Frequently Asked Questions
What is the primary focus of Aprea Therapeutics?
Aprea Therapeutics focuses on precision oncology through synthetic lethality, developing targeted therapies for various cancers.
When is the Maxim Healthcare Virtual Summit?
The summit will take place from October 15 to 17, 2024.
Who will represent Aprea at the summit?
Dr. Oren Gilad, the President and CEO of Aprea, will present at the summit.
What are the key presentations Aprea will deliver?
Aprea will participate in a Precision and Immune Oncology Panel and a Fireside Chat during the summit.
How can I attend the presentations?
You must sign up to become an M-Vest member to access the presentations live.